Welcome to our dedicated page for Centessa Pharmaceuticals Plc SEC filings (Ticker: CNTA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Centessa Pharmaceuticals plc (CNTA) SEC filings page provides access to the company’s U.S. regulatory disclosures, including current reports on Form 8‑K and related exhibits. As a Nasdaq-listed issuer with ordinary shares and American Depositary Shares registered under Section 12(b) of the Exchange Act, Centessa files documents that describe material events, financing transactions, governance matters and other information relevant to CNTA shareholders.
Recent Forms 8‑K detail items such as underwriting agreements for public offerings of American Depositary Shares, an amended and restated at-the-market sales agreement, financial results for quarterly periods, and the clearance of an Investigational New Drug (IND) application for ORX142. Filings also cover outcomes of the company’s annual general meeting, including director elections, auditor re-appointment and share allotment authorities, as well as executive employment arrangements reported under Item 5.02.
Through this page, users can review how Centessa reports progress and risks around its clinical-stage orexin receptor 2 (OX2R) agonist pipeline, capital-raising activities, and other significant corporate actions. Forms 8‑K that reference press releases often include clinical and financial updates, while accompanying exhibits such as sales agreements, underwriting agreements and legal opinions provide additional detail on transaction structures and securities law matters.
Stock Titan enhances these filings with AI-powered summaries that highlight key terms, sections and implications, helping readers quickly understand complex documents such as offering-related 8‑Ks and governance disclosures. Investors can use this resource to monitor CNTA’s regulatory reporting history, track new filings as they appear on EDGAR in near real time, and identify information relevant to their own analysis of the company.
CNTA reports a Form 144 disclosing the intended sale of 64,768 ADRs by an issuer-related party on 03/16/2026. The filing lists 1,824,968.27 and an aggregate figure 134,447,836 on the cover and shows a prior reported sale of 120,029 ADRs on 03/13/2026.
Centessa Pharmaceuticals plc Chief People Officer Karen M. Anderson exercised stock options and sold shares in a planned transaction. She exercised options for 109,398 Ordinary Shares at an exercise price of $4.01 per share and received the same number of Ordinary Shares.
On the same date, she sold 107,961 Ordinary Shares at a weighted average price of $26.1505 and 12,068 Ordinary Shares at a weighted average price of $27.1328, in multiple trades within stated price ranges. These sales were made under a Rule 10b5-1 trading plan adopted on November 12, 2025.
After these transactions, Anderson directly holds 62,085 Ordinary Shares. The exercised option, originally granted with vesting beginning on December 1, 2023, is now fully exercised, and no remaining derivative position from this option is shown in this filing.
Centessa Pharmaceuticals Chief Business Officer Gregory M. Weinhoff sold 73,196 Ordinary Shares of CNTA in open-market transactions. The sales occurred on March 13, 2026 at weighted average prices of $26.1668 and $27.1570 per share across multiple trades within disclosed price ranges.
The transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 12, 2025, indicating they were scheduled in advance. Following these sales, Weinhoff continues to hold 65,925 Ordinary Shares directly.
CNTA reports a proposed sale of ADRs under Form 144. The filing lists 120,029 ADRs with an aggregate value of $3,103,949.94 and a filing date of 03/13/2026. The notice shows securities tied to an exercise of stock options (109,398 ADRs) on 03/13/2026 and vested RSUs (10,631 ADRs) dated 02/01/2026.
The broker/dealer named is UBS Financial Services Inc. in Weehawken, NJ, and the ADRs are traded on Nasdaq. This Form 144 is a regulatory notice of an intended sale; timing and final execution are determined by the selling holder and market conditions.
UBS Financial Services Inc. submitted a Form 144 for Common stock of CNTA, listing multiple RSU vesting entries with specific share counts and vest dates. The notice enumerates vest events dated between 09/30/2022 and 02/01/2026 with per‑event share quantities.
Centessa Pharmaceuticals plc reports a large institutional holder through an amended Schedule 13G. Avoro Capital Advisors LLC and Behzad Aghazadeh together report beneficial ownership of 14,555,555 American Depositary Shares (ADSs), representing 9.97% of the ordinary shares.
The percentage is based on 146,049,056 ordinary shares outstanding as referenced in a company prospectus supplement filed on November 13, 2025. The reporting persons state the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Centessa.
Centessa Pharmaceuticals plc outlines final arrangements with former Chief Executive Officer Saurabh Saha, M.D., Ph.D., following his previously disclosed departure effective January 1, 2026. On February 9, 2026, the company entered into an Advisory Agreement and a Separation Agreement with Dr. Saha.
Under the Advisory Agreement, Dr. Saha will provide advisory services for an initial six-month term, automatically continuing unless terminated, at an hourly fee of $376.00 plus reimbursed business expenses. The Separation Agreement provides vesting of equity grants scheduled to vest on or before February 2, 2026, with later-vesting equity forfeited, and an exercise period of three months after the advisory role ends.
The Separation Agreement also includes, subject to Compensation Committee approval, a bonus equal to 100% of Dr. Saha’s target bonus for the year ended December 31, 2025, and continued eligibility for applicable company benefit plans. These extended benefits replace other severance or noncompetition payments under prior agreements and are conditioned on a general release of claims becoming effective after a seven-business-day revocation period.
FMR LLC has filed an amended Schedule 13G reporting beneficial ownership of 10,999,793 shares of Centessa Pharmaceuticals plc common stock, representing 12.2% of the class. FMR LLC holds sole voting power over 10,988,411 shares and sole dispositive power over 10,999,793 shares.
Abigail P. Johnson is also listed as a reporting person with sole dispositive power over 10,999,793 shares but no voting power. The securities are certified as acquired and held in the ordinary course of business and not for the purpose of changing or influencing control of Centessa.
FMR LLC has filed an amended Schedule 13G reporting beneficial ownership of 8,894,939 shares of Centessa Pharmaceuticals plc common stock, representing 9.9% of the class as of the stated event date. FMR reports sole voting and dispositive power over these shares.
Abigail P. Johnson is also listed as a reporting person with sole dispositive power over the same 8,894,939 shares but no voting power. The filing states the shares are held in the ordinary course of business and not for the purpose of changing or influencing control, and that one or more other persons may receive dividends or sale proceeds, with no single such person holding more than five percent of the class.
Centessa Pharmaceuticals plc reported that its Chief Medical Officer, Stephen Kanes, received an equity grant in the form of restricted share units. On February 2, 2026, he was awarded 120,000 Ordinary Shares at a price of $0 per share, bringing his directly held beneficial ownership to 120,000 Ordinary Shares.
The award consists of RSUs issued under Centessa’s Amended and Restated 2021 Stock Option and Incentive Plan. Each RSU represents the right to receive one Ordinary Share. The RSUs will vest and be settled in four equal annual installments, with the first installment vesting on February 2, 2027, aligning compensation with long‑term company performance.